Arturo Casadevall, professor at Johns Hopkins Bloomberg School of Public Health, on the debate over convalescent plasma as an effective treatment for COVID-19.

The U.S. death toll from the coronavirus topped 200,000 Tuesday, by far the highest in the world, hitting the once-unimaginable threshold.

Developing, testing and distributing a vaccine is normally a years-long process, but the public need for a COVID-19 vaccine has triggered an unprecedented, accelerated response.

Keshia M. Pollack Porter, PhD, MPH, associate dean for faculty and professor at the Johns Hopkins Bloomberg School of Public Health, on a second public health revolution.

STAT describes possible turning points that could steer the pandemic onto a different course or serve as barometers for how the virus is reshaping our lives.

Dr. Amesh A. Adalja, Johns Hopkins Center for Health Security, on the latest developments in coronavirus and the vaccine race.

The coming months of the pandemic could be catastrophic. The U.S. still has ways to prepare.

As the pandemic continues to put millions at risk daily, including health-care workers, older people and those with pre-existing diseases, who should get vaccinated first?

Johns Hopkins Bloomberg School of Public Health Professor and Virologist Andrew Pekosz on the ebb and flow of COVID-19 in the United States as the nation nears 200,000 virus deaths and steps to try to avoid a second wave of infections.

Dr. Naor Bar-Zeev, associate professor at John Hopkins' Department of International Health, on timelines for a potential COVID-19 vaccine.

New data reveal Americans’ enthusiasm is consistently falling regarding the coronavirus vaccine.

Volunteer vaccine trials with Pfizer-BioNTech for COVID-19 will be starting this week on Navajo.